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ABSTRACT 
Cilinidipine is a fourth generation N and L-type calcium channel antagonists used alone or in combination with another drug to treat 
hypertension. Cilnidipine is poorly water -soluble, BCS class II drug with 6 to 30 percent oral bioavailability due to first pass metabolism. So to 
protect the drug from degradation and improve its dissolution, solid lipid nanoparticles were prepared. Glyceryl monostearate  was selected as 
lipid while span 20: tween 20 were selected as surfactant blends. The formulations were evaluated for various parameters, as percent 
transmittance, drug content, percent encapsulation efficiency; percent drug loading,  In vitro drug release and particle size. Optimized 
formulation was lyophilized using lactose as a cryo-protectant. The lyophilized formulation was evaluated for micromeritic properties, particle 
size and in vitro dissolution. It was further evaluated for DSC, XRD, and SEM. Percent encapsulation efficiency and percent drug loading of 
optimized formulation (F3) were 78.66percent and 9.44percent respectively. The particle size of F3 formulation without drug w as 204 nm and 
with the drug was 214 nm. The particle size of the reconstituted SLN was 219 nm. In DSC study, no obvious peaks for cilnidipine were found in 
the SLN of cilnidipine indicated that the cilnidipine must be present in a molecularly dissolved state in SLN. In X-ray diffractometry absence of 
peaks representing crystals of cilnidipine in SLN indicated that the drug was in an amorphous or disordered crystalline phase in the lipid 
matrix. Thus, solid lipid nanoparticle formulation is a promising way to enhance the dissolution rate of cilnidipine.  
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INTRODUCTION 
Hypertension also called a silent killer is one of the most 
important risk factors for cardiovascular disease, a leading 
cause of death1. Various classes of a drug as diuretics, α-
blockers, b-blockers, angiotensin-converting enzyme (ACE) 
inhibitors, angiotensin II type 1 receptor blockers (ARB), 
and organic calcium channel blockers (CCBs) are used alone 
or in combination for the treatment of hypertension. Short-
acting calcium channel antagonists decrease the blood 
pressure by vasodilation but are unable to decrease the 
blood pressure associated with sympathetic overactivity 
which is a secondary to the vasodilation1,2. To lessen or 
avoid the neurohormonal activation caused by short-acting 
calcium channel blockers (CCB), fourth generation 
dihydropyridine (DHP) based N and L-type calcium channel 
antagonists like cilnidipine have been developed that have 
potential clinical benefits: gradual onset of action and a long 
duration of effects along with renal protection by decreasing 
the activity of the sympathetic nervous system (SNS) and the 
renin-angiotensin system2,3,4. Cilnidipine is highly lipophilic, 
BCS class II drug with very low water solubility, which limits 
the dissolution rate of cilnidipine in water and in turn oral 
bioavailability. All calcium channel blocker undergoes 
extensive hepatic first-pass metabolism5, and are also 
substrates for p-glycoprotein resulting in limited oral 
bioavailability. Solid lipid nanoparticles(SLN) dissolve the 
lipophilic drug in lipid which protects the drug from 
enzymatic degradation and facilitates the transport of drug 
through lymphatic route thus avoids the hepatic first pass 
metabolism6,7,8. 
MATERIAL AND METHODS 
Cilnidipine was obtained as gift sample from JB Chemical, 
Mumbai, India Labrafil 1944, Compritol, Precirol were 
obtained as gift samples from Gattefosse Corporation, 
France, poloxamer 407 was obtained from BASF India, oleic 
acid, Tween 20, Tween 80, propylene glycol, polyethylene 
glycol, Span 60, isopropyl myristate, ethyl oleate, isopropyl 
palmitate, and glyceryl monostearate, were purchased from 
Research Lab Ltd. All other chemicals used were of analytical 
grade. 
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Formulation of solid lipid nanoparticle (SLN) of 
cilnidipine:  
 Solubility Study of cilnidipine in solid lipid and 
surfactant6: 
The solubility of cilnidipine in various lipids, hydrophilic 
surfactants, and lipophilic surfactants was checked. 
Solubility in lipid was checked in molten lipid at 700C. The 
solubility of cilnidipine in surfactants was determined by 
using the shaking method. An excess amount of cilnidipine 
was added into each 5 ml vial containing 2 ml of selected 
vehicle i.e. surfactants separately and vortexed for 10 min. to 
facilitate proper mixing. The mixture vials were then kept at 
25 ± 1.0o C in an orbital shaker (Remi, CIS 24 B2) for 72 h to 
reach equilibrium. The equilibrated samples were removed 
from the shaker and centrifuged at 3000 rpm for 15 min, 
followed by filtration through a 0.45µ membrane filter. The 
filtrate was suitably diluted with methanol and absorbances 
were measured using UV visible spectrophotometer 
(Shimadzu 1700) at 240 nm. The content of cilnidipine in 
each vehicle was determined using a standard calibration 
curve of cilnidipine in methanol. From the solubility study 
lipid, hydrophilic surfactant and lipophilic surfactant 
showing a maximum solubility were selected for further 
study. 
Selection of Smix6: 
 Each surfactant blend was blended in a concentration giving 
a required HLB of GMS to form a clear microemulsion. 
Lipophilic surfactant was mixed with lipid in a vial and 
hydrophilic surfactant was added to 1 ml water in a 50 ml 
beaker. 1 ml of water was then slowly added to the lipid 
phase in a vial kept on a magnetic stirrer. The temperature 
of the oil phase and the water phase was kept 70o C. 
Selection of surfactant and optimization of surfactant 
concentration in water7: 
1ml of clear microemulsion maintained at 700C was added to 
50 ml medium (water) containing hydrophilic surfactant 
maintained at 20C under high-speed stirrer rotating at 
16,000 rpm. Addition of a drop of microemulsion to cold 
water results in solidification of the microemulsion. These 
microemulsified solid drops under high-speed stirring 
breaks into small particles resulting in the formation of solid 
lipid nanoparticles. Surfactant concentration in 50 ml cold 
water was optimized so as to prevent aggregation of solid 
lipid nanoparticles and imparting stability to a formulation. 
Two surfactants i.e. tween 20 and poloxamer 407 were 
selected and their effect on stability was studied. The 
concentration of Smix was optimized from the percent 
transmittance and stability study. 
Optimization of lipid concentration: 
Lipid concentration had a pronounced effect on particle size, 
in vitro drug release, drug content and drug entrapment 
efficiency. Lipid: Smix concentration was varied from 1:1 to 
1:5. Lipid concentration was optimized from a percent 
transmittance and stability study. 
 
Table 1: Lipid: Smix ratio 
Codes Drug Lipid: mix Lipid(GSM) 
percent 
Smix percent Water 
percent Tween 20 Span 20 
F1 1.477 0.5:0.5(1:1) 24.63 16.00 8.62 49.2 
F2 1.477 0.67:1.33(1:2) 16.42 21.34 11.49 49.2 
F3 1.477 0.5:1.5(1:3) 12.31 24.01 12.93 49.2 
F4 1.477 0.4:1.6(1:4) 9.85 25.61 13.79 49.2 
F5 1.477 0.33:1.66(1:5) 8.20 26.68 14.36 49.2 
 
The formula for suspension: 
The suspension formulation of cilnidipine was prepared 
(Table 2) and used to compare the dissolution efficacy of 
SLN formulation. 
Table 2: Formulation of suspension 
Ingredients Quantity 
Cilnidipine 0.5 g 
Sodium CMC 0.1556 g 
Veegum 0.156 g 
Sorbitol solution (70percent) 05.2 ml 
Disodium EDTA 0.01 g 
Water 50 ml 
 
Evaluation of solid lipid nanoparticles: 
 Appearance9: 
The appearance of the SLN formulations was observed for 
any turbidity or precipitation of drug. 
Spectroscopic characterization of optical clarity9.10:  
The percent transmittance of SLN formulation was 
measured using U.V. Spectrophotometer (UV-1700 
Shimadzu) at 400 nm. 
Drug content10,11: 
5 ml of solid lipid nanoparticles formulation was added to 80 
ml of methanol. It was heated so that glyceryl monostearate 
becomes soluble in hot methanol. The drug present inside 
glyceryl monostearate comes outside in methanol. Methanol 
was again cooled to room temperature so that glyceryl 
monostearate precipitates out. It was then filtered out 
through 0.45µ membrane filter paper. Volume was then 
adjusted to 100 ml in volumetric flask and absorbance is 
noted at 240nm. 
Percent Encapsulation efficiency and percent drug 
loading 6: 
A certain volume of cilnidipine solid lipid nanoparticle was 
accurately taken, dissolved, heated, filtered and diluted with 
methanol. The resulting solution was determined with UV-
Vis spectrophotometer (UV-1700 Shimadzu) at 240 nm and 
the total amount of cilnidipine was obtained. The same 
volume of cilnidipine solid lipid nanoparticles was 
accurately taken in dialysis membrane and it was tied at 
both the end. It was then suspended in a beaker containing 
100 ml methanol. The free drug gets dissolve in methanol 
and diffuses out through the dialysis membrane. Absorbance 
was then noted at 240 nm giving the concentration of a free 
drug.  
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Ws = Total drug – free drug 
 Ws        x   100 
Entrapment efficiency (percent) =      
                                                                             Wtotal 
Ws          X     100 
DL (percent) =        
                                           Wlipid 
Ws: the amount of cilnidipine loaded in SLN, 
Wtotal : total cilnidipine in cilnidipine SLN, 
Wlipid :the weight of the vehicle  
 In vitro release study11,12: 
Solid lipid nanoparticles formulation equivalent to 5 mg of 
cilnidipine entrapped in dialysis membrane were studied for 
drug release profiles in 500 ml 0.1N HCl solution using 
USPXXIII type II dissolution apparatus (DA-3D, Veego) 
rotating at 50 rpm maintained at 37±0.50C. Samples were 
withdrawn at predetermined time intervals and analyzed 
spectrophotometrically using U.V. spectrophotometer (UV-
1700 Shimadzu) at 245nm. Similar drug release profiles in 
500 ml phosphate buffer (pH 6.8) were calculated using U.V. 
spectrophotometer (UV-1700 Shimadzu) at 245nm. A 
similar procedure was carried out to perform in vitro drug 
release of suspension of cilnidipine. 
Freeze-drying of Solid lipid nanoparticles13: 
To improve the physical and chemical stability of these 
systems water has to be removed from it. The most 
commonly used process which allows converting solutions 
or suspensions into solids of sufficient stability for 
distribution and storage in the pharmaceutical field is 
freeze-drying. Some of the cryoprotectants used in literature 
for the freeze-drying of nanoparticles are glucose, sucrose, 
trehalose, lactose, mannitol, sorbitol, Aerosil (colloidal 
silicon dioxide), maltose, poly (vinyl pyrrolidone), fructose, 
dextran, poly(vinyl alcohol), hydroxypropyl-β-cyclodextrin 
and gelatin. The cryoprotectant used here was lactose. The 
SLN suspension in distilled water was cooled and froze 
stepwise from 250C to - 100C for 4 h. The primary drying 
involves drying of frozen product stepwise from -100C for 40 
h to 00C for 16 h to 100C for 5 h. secondary drying was 
performed at 250C for 10 h. 
Evaluation of solid lipid nanoparticles (freeze-dried):  
 Micromeritic properties13:  
Freeze dried formulation was analyzed for micromeritics 
properties like the angle of repose, bulk density and tapped 
density, Hausner’s ratio, and percent compressibility.  
Morphological analysis of SLN13: 
The samples were fixed on a brass disc using the double-
sided adhesive tape and were made electrically conductive 
by coating in a vacuum with platinum using JFC-1600 auto 
fine coater for 240s at 15mA. The outer macroscopic 
structure of the SLN was investigated by Scanning Electron 
Microscopy (SEM) using a Scanning Electron Microscope 
(JEOL JSM- 6360, Japan), operating at 20 KV. 
Thermal analysis13,14:  
Thermal analysis of SLN was carried out using differential 
scanning calorimeter (Mettler STARe SW 9.20 system) with a 
liquid nitrogen cooling accessory. The analysis was 
performed under a purge of dry nitrogen gas (40 cc/min). 
The sample 2mg-4mg was placed in a flat bottom aluminum 
pan and was firmly crimped with a lid to provide an 
adequate seal. The sample was heated from ambient 
temperature 400C to 2500C at a pre-programmed heating 
rate of 100C/min.  
X-ray powder diffraction12,13:  
An X-ray diffractometer (Bruker axs, model D8 advance) 
consisting of 40kV, 40mA generator with a Cu-K α radiation 
anode tube was used. Diffraction pattern  of SLN was 
scanned over 2ϴ ranges from 50 to 500 at a rate of 10C per 
min. and 0.10 2ϴ step size.  
Drug content estimation10,11:  
SLN formulation equivalent to 5 mg of cilnidipine was 
dispersed in 80 ml of methanol. The samples were mixed 
thoroughly to dissolve the drug in methanol. It was heated 
so as to dissolve GMS. It was again cooled and volume was 
adjusted to 100 ml with methanol. It was then filtered using 
0.45 µ membrane filter, suitably diluted with methanol and 
analyzed using UV visible spectrophotometer (Shimadzu 
1700) at 240 nm. 
In vitro drug release11,12: 
SLN formulation equivalent to 5 mg of cilnidipine in the 
capsule were studied for drug release profiles in 500 ml 0.1N 
HCl solution using USPXXIII type II dissolution apparatus 
(DA-3D, Veego) rotating at 50 rpm maintained at 37±0.50C. 
Samples were withdrawn at predetermined time intervals 
and analyzed spectrophotometrically using 
U.V.spectrophotometer (UV-1700 Shimadzu) at 245nm. 
Similar drug release profiles in 500 ml phosphate buffer (pH 
6.8) were calculated using U.V spectrophotometer (UV-1700 
Shimadzu) at 245nm.  
The Droplet size of reconstituted emulsions15: 
The average droplet size, size distribution of resulting 
emulsions formed from SLN was assessed by photon 
correlation spectrometer (Mastersizer 2000, Malvern Ltd). 
Stability study of reconstituted SLN formulation14: 
The optimized reconstituted SLN formulation was put into 
empty gelatine capsules and subjected to stability study at 
400C/75percent RH. Samples were charged in stability 
chambers with humidity and temperature control. The 
samples were withdrawn at 0, 15th, 30th and 45th days and 
were analyzed for appearance, in vitro drug release and 
percent transmittance. 
RESULT AND DISCUSSION  
The solid lipid nanoparticle formulation consisted of lipid 
and surfactant blend. The prior step before the formation of 
solid lipid nanoparticle is a formulation of the 
microemulsion. The microemulsion so formed should be 
clear. Solubility studies were aimed at identifying suitable 
lipid phase and surfactant/s for the development of 
cilnidipine SLN. Identifying the suitable lipid, surfactants/co-
solvent having the maximal solubilizing potential for a drug 
under investigation is very important to achieve optimum 
drug loading and also to minimize the final volume of SLN. 
The solubility of cilnidipine in various lipids, surfactants 
were determined. The data demonstrated that solubility of 
the lipophilic drug cilnidipine (Log P-5.54)4 was found to be 
higher in glyceryl monostearate. Among the hydrophilic 
surfactants tested in this study, tween 20, a medium-length 
alkyl chain with HLB 16.7 was selected as appropriate 
surfactant because non-ionic surfactants are less toxic than 
ionic surfactants14, has good biological acceptance; is 
powerful permeation enhancer, less affected by pH and ionic 
strength, and good solubilizer of cilnidipine.  Tween 20 
Bhalerao et al                                                                                                         Journal of Drug Delivery & Therapeutics. 2019; 9(3):212-221 
ISSN: 2250-1177                                                                                  [215]                                                                                 CODEN (USA): JDDTAO 
inhibits P-glycoprotein efflux of drug and thus increases 
bioavailability13. Among the lipophilic surfactant transcutol 
P and span 20 showed a good solubility.  
Table 3-Solubility of cilnidipine in different lipids, 
hydrophilic /lipophilic surfactants 
Lipid/ surfactants *Solubility of 
cilnidipine in mg/ml 
Glyceryl monostearate  10  
Precirol 3 
Compritol 2 
Tween 20 126.01 ± 0.89 
Tween 80 91.381 ± 0.98 
Tween 60 85.31 ± 1.12 
Transcutol P 88.93 ±1.15 
Span 20 26.41 ±0.80 
Span 60  28.21 ± 0.92 
                                       * Represents mean ± S.D. (n = 3) 
The solubility of cilnidipine in surfactants was determined 
by diluting respective filtrate with methanol and estimated 
using UV spectrophotometer at ʎ max 240nm. Upon 
scanning the ʎ max of cilnidipine in the presence of various 
surfactants; it was observed that there was no shift in ʎ max 
of cilnidipine. It can be inferred that selected vehicles did not 
interfere with the analytical method of the drug. 
From the solubility study, glyceryl monostearate was 
selected as a lipid for cilnidipine SLN. Hydrophilic and 
lipophilic surfactant blend was selected one which one 
forms clear microemulsion. Formation of the clear 
microemulsion is a pre-requisite for the formation of solid 
lipid nanoparticles. 
Formation of microemulsion: 
The microemulsion formed by using span 60 and tween 60 
was not clear. So it was not selected for further studies. The 
microemulsions formed by using span 20 and tween 20 and 
by using transcutol P and tween 20 were clear. So they were 
used for further studies.  
The volume of medium: 
The volume of medium given in literature varies from 25ml 
to 50ml. It is reported that greater the hydrophilicity of a 
medium, greater is the stability of solid lipid nanoparticles12. 
Hence, 50ml medium i.e. water was selected to disperse 1ml 
of microemulsion maintained at 70oC for uniform dispersion 
of solid lipid nanoparticles. 
Selection of surfactant and optimization of surfactant 
concentration in water: 
Two surfactants were selected for the study. They are 
poloxamer 407 and tween 20. The surfactant and surfactant 
concentration which was required to be added in 50ml 
water so as to dispersed microemulsion drop uniformly 
under high-speed stirrer was decided from the one showing 
maximum transmittance and stability. The concentration of 
both surfactants was varied from 0.2% to 1.0 %. 
 
Table 4: Percent Transmittance and Stability study 
Sr no 
 
Percent Surfactant 
concentration in 
the polar phase 
Percent         Transmittance Stability (at room temperature) in terms of 
no  days 
Poloxamer    407 Tween 20 Poloxamer407 Tween 20 
1 0.2 51 62 Unstable Unstable  
2 0.4 54 66 Unstable Unstable 
3 0.6 58 71 Unstable Unstable 
4 0.8 62 74 Stable   (3days) Stable (5days) 
5 1.0 66 78 Stable   (5days) Stable (7days) 
           
From percent transmittance, it was found that the same 
concentration of poloxamer 407 showed less percent 
transmittance than tween 20. Percent transmittance 
increases with an increase in surfactant concentration in 
case of both surfactants.  From stability studies, it was found 
that stability with poloxamer 407 having the same 
concentration as that of tween 20 was less. Stability was also 
found to increase with an increase in the concentration of 
surfactant in case of poloxamer 407 and tween 20. From 
percent transmittance and stability studies, tween 20 was 
selected as a surfactant, and its concentration selected for 
further studies was 1.0percent. 
Optimizations of surfactant blend in microemulsion: 
Two surfactant blend i.e. span 20: tween 20 and transcutol 
P: tween 20 showed good clarity. Selection of one surfactant 
blend was further based on stability study. The surfactant 
blend which does not show aggregation of nanoparticles for 
a long time was selected as a choice of surfactant blend.  
 
Table 5: Optimization of the surfactant blend 
Sr no. Surfactant blend Stability study presence of clarity 
in terms of number of days 
Transmittance study  
(percent) 
1 Span20: Tween20 Stable for more than one day  78 
2 TranscutolP: Tween20 Stable for one day 86 
 
From the clarity study, it was observed that span 20: tween 
20 showed greater stability than transcutol P: tween 20.The 
percent transmittance obtained with transcutol P: tween 20 
was greater than span 20: tween 20. Selected Smix was span 
20: tween 20 as it showed greater stability. These Smix 
selected from the stability point of view of nanoparticles 
which should be greater. 
Effect of lipid on percent transmittance: 
Effect of lipid on percent transmittance was checked by 
changing the lipid: Smix concentration. 
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Table 6: Change in Percent Transmittance with a change 
in lipid concentration 
Sr no. Formulation code Percent transmittance 
1. F1 74 
2. F2 78 
3. F3 81 
4. F4 83 
5. F5 89 
 
The percent transmittance was found to increase from F1 to 
F5. This increase in percent transmittance was due to an 
increase in Smix concentration from F1 to F5. Increase in 
concentration of Smix may be resulting in smaller particle 
size and hence increase percent transmittance.   
Drug content: 
Formulation code containing lipid: Smix concentration from 
F1 to F5 were evaluated for drug content. 
Table 7: Drug content of formulated SLN 
Sr no. Formulation code *Percent drug content 
1 F1 98.04 ± 1.02 
2 F2 99.12 ±0.76 
3 F3 98.86 ± 0.88 
4 F4 98.58 ± 1.21 
5 F5 97.45 ± 1.34 
* Represents mean ± S.D. (n = 3) 
 
The drug content of all the formulation i.e. from F1 to F2 was 
within 97% to 100%. 
Encapsulation efficiency and Drug loading: 
Formulation codes containing lipid: Smix concentration from 
F1 to F5 were evaluated for encapsulation efficiency and 
drug loading. 
 
Table 8 Percent encapsulation efficiency & percent Drug loading of formulated SLN 
Sr no. Formulation code Percent encapsulation efficiency Percent of drug loading 
1 F1 84.00 5.04 
2 F2 80.66 7.20 
3 F3 78.66 9.44 
4 F4 67.33 10.10 
5 F5 61.66 11.08 
 
The percent encapsulation efficiency was found to decrease 
from F1 to F2 and percent drug loading was found to 
increase from F1 to F2. Formulation F3 showed good percent 
encapsulation efficiency and percent drug loading. 
In vitro release study: 
The dissolution study of solid lipid nanoparticles is 
compared with the suspension of a drug. 
 
      
 Fig 1 In vitro drug release study of formulated SLN in 0.1N HCl 
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Figure 2: In vitro release study of formulated SLN in phosphate buffer pH 6.8 
 
The in vitro drug release of all formulation (F1 to F5) was 
found to be greater in 0.1N HCl than in phosphate buffer pH 
6.8. In vitro drug release of cilnidipine SLN was showed 
sustained and improved drug release as compared to 
cilnidipine suspension. F4 and F5 showed marginally 
increase in drug release when compared with F3.  These 
may be due to high surfactant concentration which will give 
finer particle size and greater hydrophilicity. Solid lipid 
nanoparticles adhere to the GI membrane or get 
accumulated in intervillar spaces of GI membrane16. Hence, 
they show sustain release of the drug. So, a high 
concentration of surfactant would cause GI irritation.  
So, F3 batch was selected with intermediate lipid: Smix 
concentration which was showing satisfactory percent 
encapsulation efficiency, percent drug loading and in vitro 
drug release. 
 
Particle size analysis of solid lipid nanoparticles 
 
d(0.1): 0.067 μm d(0.5):0.118 μm d(0.9): 0.204 μm 
Figure 3: Particle size analysis of F3 formulation without drug 
 
d(0.1): 0.069 μm d(0.5):0.119 μm d(0.9): 0.214 μm 
Figure 4: Particle size analysis of F3 formulation withh drug 
The particle size of F3 without drug was 204 nm, while with 
the drug it was 214 nm. After the addition of the drug, there 
was marginal increase in the particle size of solid lipid 
nanoparticle. 
Formulation of Solid lipid nanoparticles by freeze-drying 
method: 
Formulation F3 was subjected to freeze drying. Lactose was 
used as a carrier as it has good flow properties, surface area, 
and it is also used as a cryoprotectant in freeze drying.  
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The Formulation for freeze-drying: 
Formulation ready for freeze drying consisted of 2 gm 
system (i.e. F3) dispersed in 50 ml water to which 1 gm of 
lactose was added. This formulation was used for freeze 
drying. 
Micromeritics Properties: 
Appearance: The freeze-dried SLN were white, non gritty 
powder
Table 8 Micromeritic properties of optimized formulation 
Formulation Angle of 
Repose (ϴ) 
Bulk density 
(g/cm
3
) 
Tapped density 
(g/cm
3
) 
Hausner’s 
ratio 
Carr’s index 
(percent) 
2:1 32.14 0.533 0.59 1.42 30.72 
 
From the results of the angle of repose, Hausner's ratio and 
Carr's index it indicated that powder possessed satisfactory 
flow properties. 
The Particle size of reconstituted SLN: 
The mean globule size of reconstituted solid lipid 
nanoparticles is presented by Freeze drying method. 
There was a slight increase in particle size after 
reconstitution of solid lipid nanoparticles as compared to 
liquid-solid lipid nanoparticle. Reconstituted solid lipid 
nanoparticles showed a particle size of 219 nm while liquid-
solid lipid nanoparticle showed particle size of 214 nm.
 
 
d(0.1): 0.071 μm d(0.5):0.125 μm d(0.9): 0.219 μm 
Figure 5: Particle size analysis of reconstituted formulation F3 
Morphological analysis of solid SLN: 
 
A) SEM of Cilnidipine                        B) SEM of Lactose 
 
                                                                  C) SEM of Freeze dried SLN 
Figure 5: Scanning electron micrographs: (A) Cilnidipine; (B) Lactose; (C) SLN by Freeze drying method 
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Cilnidipine is rectangular plate shaped rough surface 
crystals. Lactose was detected as aggregates of amorphous 
particles and with a smooth surface. SLN appeared as rough 
surfaced lactose particles, indicating that the SLN is adsorbed 
on lactose. 
Differential Scanning Calorimetry (DSC): 
The physical state of cilnidipine in the SLN was investigated 
since it would have an important influence on the in-vitro 
and in-vivo release characteristics. Pure cilnidipine showed a 
sharp endothermic peak at temperature 1080C-1110C in DSC. 
No obvious peaks for cilnidipine were found in the SLN of 
cilnidipine. It might be explained that the crystallization of 
cilnidipine was inhibited by lactose and surfactants. This also 
indicates that the cilnidipine must be present in a 
molecularly dissolved state in solid SLN. 
 
 
Figure 6: Differential scanning calorimetric thermographs of cilnidipine, lactose, solid SLN prepared by Freeze drying 
method 
DSC of pure lactose showed a first endothermic peak in the 
range of 145oC to 150oC which was due loss of water 
molecule and second endothermic peak in the range of 215oC 
to 220oC which was due to the melting of lactose. DSC of the 
drug showed melting of the drug started at 108oC. DSC of 
SLN showed no endothermic peak for drug indicating that 
crystallization of cilnidipine was inhibited by lactose and 
surfactants. Loss of water molecule from lactose due to 
freeze-drying (DSC of SLN), it did not show a peak in the 
range of 145oC to 150oC. There was a slight shift in the peak 
of lactose in formulation from 218oC to 236oC. It might be 
due to charring of carbohydrate i.e. lactose. From these, we 
can conclude that the crystallinity of lactose has been 
suppressed but not totally. 
 
X-ray powder diffractometry: 
A     B  
C   
Figure 7: X-ray powder diffractometry of (A) Cilnidipine; (B) Lactose; (C) SLN prepared by Freeze drying method 
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The results showed the absence of obvious peaks 
representing crystals of cilnidipine in SLN indicating that the 
drug was in an amorphous or disordered crystalline phase in 
the lipid matrix. The intensity of lactose peak in SLN was also 
decreased as compared to X-ray of pure lactose, indicating 
that crystallinity of lactose has been suppressed but not 
totally. 
Drug content of SLN formulations: 
Drug content of reconstituted SLN formulations prepared by 
the freeze-drying method was calculated using a calibration 
curve of cilnidipine in methanol. 
Table 8 Drug content of SLN formulations prepared by Freeze drying method 
    Formulation Conc. of Lactose 
(mg) 
SLN formulation 
(mg) 
*Drug content 
(percent) 
F3 1000 2000 98.27± 0.98 
* Represents mean ± S.D. (n = 3) 
The preparation of Freeze dried SLN from liquid SLN did not significantly affect the drug content of the formulations. 
 
Figure 8: In vitro drug release profiles of SLN formulation (F3) prepared by freeze drying method in 0.1N HCl and 
phosphate buffer pH 6.8 
Freeze dried formulation F3 showed 69.24percent drug release and 63.42percent drug release in 0.1N HCl and phosphate 
buffer pH 6.8 respectively.  
Stability study: 
The SLN formulation F3 was selected for the stability study. Formulation F3 was stable up to 45days. 
Table 9: Stability study of SLN (F3) 
Sampling point       
(days) 
percent 
drug content 
*percent drug 
release in 480 min. 
in 0.1N HCl 
*percent drug release 
in 60 min. in pH 6.8 
Phosphate buffer 
percent 
Transmittance 
0 99.20±0.68 67.32±0.12     60.48±0.15 74.54 
15 99.43±0.12 66.95±0.23     60.12±0.43 75.12 
30 99.03±0.20 68.14±0.45 61.32±0.54 72.86 
45 98.07±0.14 67.94±0.65     62.23±0.76 71.09 
       * Represents mean ± S.D. (n = 3) 
CONCLUSION 
It can be concluded that solid lipids nanoparticles are promising ways to enhance the dissolution rate of cilnidipine. 
ACKNOWLEDGEMENT 
We are thankful to Pad. Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, for providing facilities to 
carry out this research work 
CONFLICT OF INTEREST-None 
 
 
 
 
0
10
20
30
40
50
60
70
80
0 200 400 600
C
u
m
u
la
ti
ve
 %
 d
ru
g 
re
le
as
e
 
Time (min) 
F3 in 0.1N HCl
F3 in Phosphate buffer pH 6.8
Bhalerao et al                                                                                                         Journal of Drug Delivery & Therapeutics. 2019; 9(3):212-221 
ISSN: 2250-1177                                                                                  [221]                                                                                 CODEN (USA): JDDTAO 
REFERENCES 
1. Uneyama H, Uchida H, Konda T, Yoshimoto R. Cilnidipine: 
Preclinical profile and clinical evaluation. Cardiovascular drug 
reviews. 1999; 17(4):341-57. 
2. Sakaki T, Naruse H, Masai M, Takahashi K, Ohyanagi M, Iwasaki 
T, Fukuchi M. Cilnidipine as an agent to lower blood pressure 
without sympathetic nervous activation as demonstrated by 
iodine-123 metaiodobenzylguanidine imaging in rat hearts. 
Annals of nuclear medicine. 2003; 17(4):321-6. 
3. Chandra KS, Ramesh G. The fourth-generation Calcium channel 
blocker: cilnidipine. Indian heart journal. 2013; 65(6):691-5. 
4. Aritomi S, Koganei H, Wagatsuma H, Mitsui A, Ogawa T, Nitta K, 
Konda T. The N-type, and L-type calcium channel blocker 
cilnidipine suppresses renal injury in Dahl rats fed a high-salt 
diet. Heart and vessels. 2010; 25(6):549-55. 
5. Liu XQ, Zhao Y, Li D, Qian ZY, Wang GJ. Metabolism and 
metabolic inhibition of cilnidipine in human liver microsomes. 
Acta Pharmacologica Sinica. 2003; 24(3):263-8. 
6. Youssef T, Fadel M, Fahmy R, Kassab K. Evaluation of hypericin-
loaded solid lipid nanoparticles: Physicochemical properties, 
photostability, and phototoxicity. Pharmaceutical development 
and technology. 2012; 17(2):177-86. 
7. Houli L, Zhao X, Ma Y et al. Enhancement of gastrointestinal 
absorption of quercetin by solid lipid nanoparticles. Journal of 
Controlled Release. 2009; 133:238-44. 
8. Xia Q, Hao X, Lu Y, Xu W, Wei H, Ma Q, Gu N. Production of drug-
loaded lipid nanoparticles based on phase behaviors of special 
hot microemulsions. Colloids and Surfaces A: Physicochemical 
and Engineering Aspects. 2008; 313:27-30. 
9. Subedi RK, Kang KW, Choi KH. Preparation and characterization 
of solid lipid nanoparticles loaded with doxorubicin. European 
Journal of Pharmaceutical Science.2009; 37:508-513. 
10. Luo YF, Chen DW, Ren LX, Zhao XL, Qin J. Solid lipid 
nanoparticles for enhancing vinpocetine's oral bioavailability. 
Journal of controlled release. 2006; 114(1):53-9. 
11. Rachmawati H, Rasaputri DH, Tarini S. Preparation and 
Characterization of Folic Acid-Encapsulated. Journal 
NANOSAINS & NANOTEKNOLOGI. 2010; 3(2):37-40. 
12. Xia Q, Lu YY, Gu N. Preparation of lipid nanoparticles based on 
phase behaviors of hot microemulsions. In Solid State 
Phenomena. 2007; 121:847-50.  
13. Prabakaran L, Remya B. Formulation and characterization of 
Domperidone solid lipid nanoparticles in an aqueous system 
using micro emulsification technique. Journal of Pharmacy 
Research.2010; 3(12):2944-46 
14. Serpe L, Canaparo R, Daperno M et al. Solid lipid Nanoparticles 
as anti-inflammatory drug delivery system in human 
inflammatory bowel disease whole- blood model. European J of 
Pharmaceutical Sci. 2010; 39:428-36 
15. Li HL, Zhao XB, Ma YK, Zhai GX, Li LB, Lou H. Enhancement of 
gastrointestinal absorption of quercetin by solid lipid 
nanoparticles. Journal of Controlled Release. 2009; 133(3):238-
44 
16. Severino P, Andreani T, Macedo A et al. Current State-of-Art and 
New Trends on Lipid Nanoparticles (SLN and NLC) for Oral 
Drug Delivery. Journal of Drug Delivery.2011; 2012:1-6 
 
 
 
 
